JL

Jason Lettmann

Chief Executive Officer

ALX Oncology

Boulder, Colorado


Contact Information

Email
Unlock
LinkedIn

Company Information

Company
ALX Oncology
Industry
research
Employees
76.0
Seniority
C suite
Annual Revenue
1182000.0

Technologies

Amazon SES Gmail Google Apps Google Cloud Hosting WP Engine OneTrust Adobe Marketing Cloud reCAPTCHA Google Tag Manager Mobile Friendly WordPress.org Gravity Forms Nginx Remote Basis

Keywords

immunooncology novel biologics research & development innovation cd47 biotechnology: pharmaceutical preparations health care biotechnology research cancer treatment immunotherapy cd47 blockade evorpacept clinical trials oncology immune system anticancer therapies innate immune response solid tumors hematologic cancers checkpoint inhibitors drug development biopharmaceutical anti-cancer antibodies monoclonal antibodies biotechnology molecular biology patient outcomes tumor recognition immune checkpoints clinical-stage therapeutic candidate innovative therapies treatment paradigm fda approval oncology pipeline phase 1 trials phase 2 trials combination therapy safety profile drug efficacy cancer research personalized medicine tumor microenvironment cancer immunology scientific innovation therapeutic agents patient lives oncology specialization biological agents biological therapies clinical data resistant cancers long half-life pharmacokinetics pharmacodynamics dendritic cells macrophages health wellness & fitness hospital & health care

Get Full Contact Details

Subscribe to reveal email addresses and export contacts.

View Plans